130773-02-3
基本信息
鹽酸奈康唑
鹽酸奈替康唑
(E)-1-(2-(甲硫基)-1-(2-(戊氧基)苯基)乙烯基)-1H-咪唑鹽酸鹽
Atolant
Neticonazole hydrochloride
1-[2-methylsulfanyl-1-(2-pentoxyphenyl)ethenyl]imidazole hydrochloride
1-[(E)-2-methylsulfanyl-1-(2-pentoxyphenyl)ethenyl]imidazole,hydrochloride
(E)-1-(2-(Methylthio)-1-(2-(pentyloxy)phenyl)vinyl)-1H-imidazole hydrochloride
long-acting,colorectal,Neticonazole,antifungal,Neticonazole Hydrochloride,Imidazole,anti-cancer,nSMase2,Fungal,secretion,Inhibitor,p-ERK,anti-infection,inhibit,exosome
物理化學(xué)性質(zhì)
報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | CAS號(hào) | 包裝 | 價(jià)格 |
2024/11/08 | HY-128365 | 鹽酸奈替康唑 Neticonazole hydrochloride | 130773-02-3 | 25mg | 650元 |
2024/11/08 | HY-128365 | 鹽酸奈替康唑 Neticonazole hydrochloride | 130773-02-3 | 50mg | 950元 |
2024/11/08 | HY-128365 | 鹽酸奈替康唑 Neticonazole hydrochloride | 130773-02-3 | 100mg | 1600元 |
常見(jiàn)問(wèn)題列表
Fungal
Neticonazole (10 μM; 48 hours; C4-2B cells) treatment decreases the levels of both Alix and Rab27a, and significantly decreases nSMase2 levels. Neticonazole causes a significant inhibition in p-ERK levels.
Neticonazole (0-10 μM) exhibits a potent and dose-dependent inhibition of exosome release from C4-2B cells.
Neticonazole hydrochloride is also an orally active exosome biogenesis and secretion inhibitor.
Western Blot Analysis
Cell Line: | C4-2B cells |
Concentration: | 10 μM |
Incubation Time: | 48 hours |
Result: | Decreased the levels of both Alix and Rab27a, and significantly decreased nSMase2 levels. |
Neticonazole (1-100 ng/kg; oral gavage; daily; for 15 days; male C57BL/6 mice) treatment significantly improves the survival of intestinal dysbacteriosis (IDB) mice with colorectal cancer (CRC) xenograft tumors, likely through increasing apoptosis of CRC xenograft tumor cells.
Animal Model: | Male C57BL/6 mice (8 weeks old) given ampicillin, neomycin, metronidazole and vancomycin, and injected with SW480 cells |
Dosage: | 1 ng/kg, 10 ng/kg and 100 ng/kg |
Administration: | Oral gavage; daily; for 15 days |
Result: | Significantly improved the survival of IDB mice with CRC xenograft tumors. |